Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.

ABSTRACT:

Objective

Immunocompromised individuals are at an increased risk of pneumococcal disease. Vaccination is recommended as an important strategy to reduce risk of pneumococcal disease in HIV-infected individuals. This study evaluated the safety and immunogenicity of three 13-valent pneumococcal conjugate vaccine (PCV13) doses followed by one dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) at 1-month intervals in pneumococcal vaccine-naive, HIV-infected individuals.

Design

This was a phase 3, open-label, single-arm study.

Methods

Pneumococcal vaccine-naive, HIV-infected individuals at least 6 years of age with CD4 T-cell count at least 200  cells/μl and viral load less than 50 000  copies/ml received three doses of PCV13 followed by one dose of PPSV23 at 1-

SUBMITTER: Bhorat AE 

PROVIDER: S-EPMC4521829 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature